Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

» Andere revante producten voor Scalda studenten en medewerkers.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

01-12-2011

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia

Auteurs: James Signorovitch, Andres Brainsky, Kelly M. Grotzinger

Gepubliceerd in: Quality of Life Research | Uitgave 10/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To assess the validity and reliability of the fatigue subscale of the Functional Assessment of Chronic Illness Therapy (FACIT-F), a 6-item subset from the thrombocytopenia subscale of the Functional Assessment of Cancer Therapy (FACT-Th6) and the Short Form-36 Version 2 (SF-36v2) in 2 clinical trials of the thrombopoietin receptor agonist eltrombopag in chronic immune thrombocytopenia (ITP) patients.

Methods

In the 6-month, RAndomized placebo-controlled ITP Study with Eltrombopag (RAISE; n = 197), the FACIT-F, FACT-Th6, and SF-36v2 were administered at baseline, day 43, weeks 14 and 26, or early withdrawal. In the ongoing open-label extension study, Eltrombopag EXTENDed Dosing Study (EXTEND; n = 154), measures were administered at baseline, at the beginning of each stage, and at permanent discontinuation of study medication.

Results

FACIT-F, FACT-Th6, and SF-36v2 demonstrated acceptable internal consistency reliability (i.e., all Cronbach’s alphas >0.70) and test–retest reliability (all intraclass correlation coefficients >0.70). Construct validity was supported by moderate (0.35 < r < 0.50) to strong (r > 0.50) inter-measure correlations for baseline and change scores. A small to medium magnitude of effect was captured by the FACIT-F and FACT-Th6 among patients who experienced sustained platelet responses.

Conclusions

Results provide support for the validity, reliability, and responsiveness of the FACIT-F, FACT-Th6, and SF-36v2 in chronic ITP patients.
vorige artikel Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
volgende artikel Reliability and validity of the Taiwan (Mandarin Chinese) version of the chronic respiratory questionnaire
Literatuur
1.
Ballem, P. J., Segal, G. M., Stratton, J. R., Gernsheimer, T., Adamson, J. W., & Slichter, S. J. (1987). Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. The Journal of Clinical Investigation, 80, 33–40.PubMedCrossRef
2.
Chang, M., Nakagawa, P. A., Williams, S. A., Schwartz, M. R., Imfeld, K. L., Buzby, J. S., et al. (2003). Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood, 102, 887–895.PubMedCrossRef
3.
Cines, D. B., & Blanchette, V. S. (2002). Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995–1008.PubMedCrossRef
4.
Feudjo-Tepie, M. A., Robinson, N. J., & Bennett, D. (2008). Prevalence of diagnosed chronic immune thrombocytopenic purpura in the us: Analysis of a large us claim database: A rebuttal. Journal of Thrombosis Haemostasis, 6, 711–712, author reply 713.
5.
Mathias, S. D., Bussel, J. B., George, J. N., McMillan, R., Okano, G. J., & Nichol, J. L. (2007). A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation. Health and Quality of Life Outcomes, 5, 11.PubMedCrossRef
6.
Mathias, S. D., Gao, S. K., Miller, K. L., Cella, D., Snyder, C., Turner, R., et al. (2008). Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: A conceptual model starting with the patient perspective. Health and Quality of Life Outcomes, 6, 13. Available at http://​www.​hqlo.​com/​content/​16/​11/​13.
7.
Bussel, J. B., Cheng, G., Saleh, M. N., Psaila, B., Kovaleva, L., Meddeb, B., et al. (2007). Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 357, 2237–2247.PubMedCrossRef
8.
Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H., & Merkel, D. E. (2002). Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24, 547–561.PubMedCrossRef
9.
Webster, K., Cella, D., & Yost, K. (2003). The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.PubMedCrossRef
10.
Cella, D., Beaumont, J. L., Webster, K. A., Lai, J. S., & Elting, L. (2006). Measuring the concerns of cancer patients with low platelet counts: The functional assessment of cancer therapy–thrombocytopenia (FACT-Th) questionnaire. Supportive Care in Cancer, 14, 1220–1231.PubMedCrossRef
11.
Ware, J. E., Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Mariush, M. E. (2007). User’s manual for the sf-36v2 health survey (2nd ed.). Lincoln, RI: Quality Metric Incorporated.
12.
Cheng, G., Saleh, M. N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., et al. (2010). Eltrombopag for the long-term management of chronic idiopathic thrombocytopenic purpura: A 6-month, randomized, phase iii study (RAISE). Lancet. Epub ahead of print.
13.
Saleh, M. N., Bussel, J. B., Cheng, G., Meddeb, B., Mayer, B., Bailey, C., et al. (2009). Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: Results from the extend study. Blood, 114, Abstract 682.
14.
Fehnel, S. E., Bann, C. M., Hogue, S. L., Kwong, W. J., & Mahajan, S. S. (2004). The development and psychometric evaluation of the motivation and energy inventory (MEI). Quality of Life Research, 13, 1321–1336.PubMedCrossRef
15.
Marra, C. A., Woolcott, J. C., Kopec, J. A., Shojania, K., Offer, R., Brazier, J. E., et al. (2005). A comparison of generic, indirect utility measures (the hui2, hui3, sf-6d, and the eq-5d) and disease-specific instruments (the raqol and the haq) in rheumatoid arthritis. Social Science and Medicine, 60, 1571–1582.PubMedCrossRef
16.
Guttman, L. (1954). Some necessary conditions for common-factor analysis. Psychometrika, 19, 149–161.CrossRef
17.
Kaiser, H. F. (1960). The application of electronic computers to factor analysis. Educational and Psychological Measurement, 20, 141–151.CrossRef
18.
Kaiser, H. F. (1961). A note on Guttman’s lower bound for the number of common factors. British Journal of Mathematical and Statistical Psychology, 14, 1.
19.
Kline, P. (1993). Handbook of psychological testing. London: Routledge.
20.
21.
Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in addressing rater reliability. Psychological Bulletin, 86, 420–428.PubMedCrossRef
22.
Cohen, J. (1977). Statistical power analysis for the behavioral science (revised ed.) New York: Academic Press.
23.
Moretti, C., Viola, S., Pistorio, A., Magni-Manzoni, S., Ruperto, N., Martini, A., et al. (2005). Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 64, 257–261.PubMedCrossRef
24.
Liang, K.-Y., & Seger, S. L. (1986). Longitudinal data analysis using generalized linear models. Biometrika, 73, 13–22.CrossRef
25.
Cella, D., Lai, J. S., Chang, C. H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general united states population. Cancer, 94, 528–538.PubMedCrossRef
26.
Guyatt, G. H., King, D. R., Feeny, D. H., Stubbing, D., & Goldstein, R. S. (1999). Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. Journal of Clinical Epidemiology, 52(3), 187–92. PubMed PMID: 10210235.
27.
McGraw, K. O., & Wong, S. P. (1996). Forming inferences about some intraclass correlation coefficients. Psychological Methods, 1, 30–46.CrossRef
Metagegevens
Titel
Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia
Auteurs
James Signorovitch
Andres Brainsky
Kelly M. Grotzinger
Publicatiedatum
01-12-2011
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 10/2011
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-9912-9

Andere artikelen Uitgave 10/2011

Application of the Oral Health Impact Profile (OHIP) among Taiwanese elderly

  • Brief Communication

Quality of life and emotional burden of primary caregivers: a case–control study of multiple sclerosis patients in Greece

Parental assessment of adolescent quality of life: can it replace self-assessment?

Participation as an outcome measure in psychosocial oncology: content of cancer-specific health-related quality of life instruments

  • Open Access
  • Review

Impaired health status and care dependency in patients with advanced COPD or chronic heart failure

  • Open Access

Impaired renal function is associated with worse self-reported outcomes after kidney transplantation